This is a prospective cohort study on the effect of Andrographis Paniculata (AP) on palliative management of patients with advanced or metastatic esophageal cancer. A total of 30 patients with locally advanced or metastatic squamous esophageal cancer will be recruited for the trial.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
30
AP as palliative treatment
Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong
Hong Kong, Outside of US & Canada, China
Symptomatic relief and quality of life after AP
Symptomatic relief of Dysphagia and quality of life after treatment Dysphagia measured by Dysphagia score Quality of Life measured by EORTC-QLQ-C30
Time frame: 4 months
Difficulty to swallow
Difficulty to swallow by dysphagia grade 0 = able to eat normal diet / no dysphagia. 1. = able to swallow some solid foods 2. = able to swallow only semi solid foods 3. = able to swallow liquids only 4. = unable to swallow anything / total dysphagia
Time frame: 4 months
Survival
Median Survival
Time frame: up to 36 months
Adverse events
Rate of adverse events
Time frame: up to 36 months
AP side effects
Side effects related to AP including 1. Gastrointestinal upset 2. Nausea and Vomiting 3. Allergy 4. Diarrhoea 5. Abdominal pain 6. Dizziness
Time frame: 4 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.